18F-Fluorodeoxyglucose Positron Emission Tomography versus Computed Tomography in Predicting Histopathological Response to Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor Treatment in Resectable Non-Small Cell Lung Cancer

Abstract

FDG-PET/CT has an advantage over CT as a predictive tool to identify histopathologic response after 3 weeks of EGFR-TKI treatment in NSCLC patients.

TLG-S criteria are superior to both EORTC and PERCIST for predicting outcomes in patients with metastatic lung adenocarcinoma treated with erlotinib

“…Consistent with previous reports [3][4][5][6][7][8][9], the results of our study demonstrate that assessment of early FDG-PET response using the EORTC criteria predicts OS in NSCLC patients treated with erlotinib. In our report, the number and timing of FDG-PET scans (at baseline and on days 14 and 56) were in line with the protocol utilized by Mileshkin et al [3].…”

“…Because several papers addressing these issues have been published [3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19], we also performed a retrospective review of our cohort data. The first goal of the retrospective analysis was to investigate whether early FDG-PET assessment of treatment response using TLG-S would be superior to either local assessment with EORTC criteria or hottest-single-lesion assessment with PERCIST criteria for predicting 2-year survival outcomes.…”

“…Several studies have shown that FDG-PET is a useful imaging modality for predicting response to erlotinib in patients with non-small cell lung cancer (NSCLC) [3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19]. However, most of these studies used only the primary tumor as the target lesion for sequential imaging [3][4][5][6][7][8][9][10][11][12], and treatment response was largely assessed using the European Organization for Research and Treatment of Cancer (EORTC) criteria [3][4][5][6][7][8][9]20]. Other studies have evaluated treatment response using the Positron Emission Tomography Response Criteria in Solid Tumors (PERCIST) [21], based on the measurement of a specific focus on the hottest single lesion, including the metastatic tumor [15,16].…”

Skin rash in patients treated with neoadjuvant erlotinib (Tarceva) in resectable non-small cell lung cancer: Predictor for tumor response and survival?

“…The M06NEL phase II study was designed to evaluate response of a short course of neoadjuvant (preoperative) erlotinib in patients with early stage NSCLC [11,12]. This study included patients with unknown EGFR mutation status from 2006 -2010, and currently mature survival data are available.…”

99mTc-3PRGD2 SPECT/CT predicts the outcome of advanced nonsquamous non-small cell lung cancer receiving chemoradiotherapy plus bevacizumab

“…Functional imaging, such as positron emission tomography/computed tomography (PET/CT) and single photon emission computed tomography/CT (SPECT/CT), can both help clinicians design individualized treatment to improve the outcome of advanced NSCLC [8][9][10]. Novel a v b 3 -specific tracers for SPECT, like technetium-99m ( 99m Tc) radiolabeled Arg-Gly-Asp (RGD) peptides and analogs, can specifically target the integrin a v b 3 , which plays a critical role in the regulation of tumor angiogenesis and metastasis [11,12].…”